Stay updated on Immune Response in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Immune Response in NSCLC Clinical Trial page.

Latest updates to the Immune Response in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to include new information about a clinical trial for pembrolizumab in treating recurrent non-small cell lung cancer, including details about the study's location and collaborators. However, significant content regarding the trial's objectives and treatment protocols has been removed.SummaryDifference41%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Immune Response in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune Response in NSCLC Clinical Trial page.